drugset
drugset / Trial / NCT04877990

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

NCT04877990 ↗

Phase 2 Completed 67 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of Deucravacitinib in participants who have previously been enrolled in a Deucravacitinib Phase 2 study for moderate to severe Crohn's disease or moderate to severe Ulcerative Colitis.

Timeline

Start
2021-05-07
Primary completion
2023-08-29
Completion
2023-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — —

Indications

Crohn disease ulcerative colitis